Cargando…

Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC

OBJECTIVE: Conflicting microbiota data exist for primary sclerosing cholangitis (PSC) and experimental models. Goal: define the function of complex resident microbes and their association relevant to PSC patients by studying germ-free (GF) and antibiotic-treated specific pathogen-free (SPF) multidru...

Descripción completa

Detalles Bibliográficos
Autores principales: Awoniyi, Muyiwa, Wang, Jeremy, Ngo, Billy, Meadows, Vik, Tam, Jason, Viswanathan, Amba, Lai, Yunjia, Montgomery, Stephanie, Farmer, Morgan, Kummen, Martin, Thingholm, Louise, Schramm, Christoph, Bang, Corinna, Franke, Andre, Lu, Kun, Zhou, Huiping, Bajaj, Jasmohan S, Hylemon, Phillip B, Ting, Jenny, Popov, Yury V, Hov, Johannes Roksund, Francis, Heather L, Sartor, Ryan Balfour
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751228/
https://www.ncbi.nlm.nih.gov/pubmed/35705368
http://dx.doi.org/10.1136/gutjnl-2021-326500
_version_ 1784850426587250688
author Awoniyi, Muyiwa
Wang, Jeremy
Ngo, Billy
Meadows, Vik
Tam, Jason
Viswanathan, Amba
Lai, Yunjia
Montgomery, Stephanie
Farmer, Morgan
Kummen, Martin
Thingholm, Louise
Schramm, Christoph
Bang, Corinna
Franke, Andre
Lu, Kun
Zhou, Huiping
Bajaj, Jasmohan S
Hylemon, Phillip B
Ting, Jenny
Popov, Yury V
Hov, Johannes Roksund
Francis, Heather L
Sartor, Ryan Balfour
author_facet Awoniyi, Muyiwa
Wang, Jeremy
Ngo, Billy
Meadows, Vik
Tam, Jason
Viswanathan, Amba
Lai, Yunjia
Montgomery, Stephanie
Farmer, Morgan
Kummen, Martin
Thingholm, Louise
Schramm, Christoph
Bang, Corinna
Franke, Andre
Lu, Kun
Zhou, Huiping
Bajaj, Jasmohan S
Hylemon, Phillip B
Ting, Jenny
Popov, Yury V
Hov, Johannes Roksund
Francis, Heather L
Sartor, Ryan Balfour
author_sort Awoniyi, Muyiwa
collection PubMed
description OBJECTIVE: Conflicting microbiota data exist for primary sclerosing cholangitis (PSC) and experimental models. Goal: define the function of complex resident microbes and their association relevant to PSC patients by studying germ-free (GF) and antibiotic-treated specific pathogen-free (SPF) multidrug-resistant 2 deficient (mdr2(−/−) ) mice and microbial profiles in PSC patient cohorts. DESIGN: We measured weights, liver enzymes, RNA expression, histological, immunohistochemical and fibrotic biochemical parameters, faecal 16S rRNA gene profiling and metabolomic endpoints in gnotobiotic and antibiotic-treated SPF mdr2(−/−) mice and targeted metagenomic analysis in PSC patients. RESULTS: GF mdr2(−/−) mice had 100% mortality by 8 weeks with increasing hepatic bile acid (BA) accumulation and cholestasis. Early SPF autologous stool transplantation rescued liver-related mortality. Inhibition of ileal BA transport attenuated antibiotic-accelerated liver disease and decreased total serum and hepatic BAs. Depletion of vancomycin-sensitive microbiota exaggerated hepatobiliary disease. Vancomycin selectively decreased Lachnospiraceae and short-chain fatty acids (SCFAs) but expanded Enterococcus and Enterobacteriaceae. Antibiotics increased Enterococcus faecalis and Escherichia coli liver translocation. Colonisation of GF mdr2(−/−) mice with translocated E. faecalis and E. coli strains accelerated hepatobiliary inflammation and mortality. Lachnospiraceae colonisation of antibiotic pretreated mdr2(−/−) mice reduced liver fibrosis, inflammation and translocation of pathobionts, and SCFA-producing Lachnospiraceae and purified SCFA decreased fibrosis. Faecal Lachnospiraceae negatively associated, and E. faecalis/ Enterobacteriaceae positively associated, with PSC patients’ clinical severity by Mayo risk scores. CONCLUSIONS: We identified novel functionally protective and detrimental resident bacterial species in mdr2(−/−) mice and PSC patients with associated clinical risk score. These insights may guide personalised targeted therapeutic interventions in PSC patients.
format Online
Article
Text
id pubmed-9751228
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-97512282023-04-01 Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC Awoniyi, Muyiwa Wang, Jeremy Ngo, Billy Meadows, Vik Tam, Jason Viswanathan, Amba Lai, Yunjia Montgomery, Stephanie Farmer, Morgan Kummen, Martin Thingholm, Louise Schramm, Christoph Bang, Corinna Franke, Andre Lu, Kun Zhou, Huiping Bajaj, Jasmohan S Hylemon, Phillip B Ting, Jenny Popov, Yury V Hov, Johannes Roksund Francis, Heather L Sartor, Ryan Balfour Gut Gut Microbiota OBJECTIVE: Conflicting microbiota data exist for primary sclerosing cholangitis (PSC) and experimental models. Goal: define the function of complex resident microbes and their association relevant to PSC patients by studying germ-free (GF) and antibiotic-treated specific pathogen-free (SPF) multidrug-resistant 2 deficient (mdr2(−/−) ) mice and microbial profiles in PSC patient cohorts. DESIGN: We measured weights, liver enzymes, RNA expression, histological, immunohistochemical and fibrotic biochemical parameters, faecal 16S rRNA gene profiling and metabolomic endpoints in gnotobiotic and antibiotic-treated SPF mdr2(−/−) mice and targeted metagenomic analysis in PSC patients. RESULTS: GF mdr2(−/−) mice had 100% mortality by 8 weeks with increasing hepatic bile acid (BA) accumulation and cholestasis. Early SPF autologous stool transplantation rescued liver-related mortality. Inhibition of ileal BA transport attenuated antibiotic-accelerated liver disease and decreased total serum and hepatic BAs. Depletion of vancomycin-sensitive microbiota exaggerated hepatobiliary disease. Vancomycin selectively decreased Lachnospiraceae and short-chain fatty acids (SCFAs) but expanded Enterococcus and Enterobacteriaceae. Antibiotics increased Enterococcus faecalis and Escherichia coli liver translocation. Colonisation of GF mdr2(−/−) mice with translocated E. faecalis and E. coli strains accelerated hepatobiliary inflammation and mortality. Lachnospiraceae colonisation of antibiotic pretreated mdr2(−/−) mice reduced liver fibrosis, inflammation and translocation of pathobionts, and SCFA-producing Lachnospiraceae and purified SCFA decreased fibrosis. Faecal Lachnospiraceae negatively associated, and E. faecalis/ Enterobacteriaceae positively associated, with PSC patients’ clinical severity by Mayo risk scores. CONCLUSIONS: We identified novel functionally protective and detrimental resident bacterial species in mdr2(−/−) mice and PSC patients with associated clinical risk score. These insights may guide personalised targeted therapeutic interventions in PSC patients. BMJ Publishing Group 2023-04 2022-06-15 /pmc/articles/PMC9751228/ /pubmed/35705368 http://dx.doi.org/10.1136/gutjnl-2021-326500 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Gut Microbiota
Awoniyi, Muyiwa
Wang, Jeremy
Ngo, Billy
Meadows, Vik
Tam, Jason
Viswanathan, Amba
Lai, Yunjia
Montgomery, Stephanie
Farmer, Morgan
Kummen, Martin
Thingholm, Louise
Schramm, Christoph
Bang, Corinna
Franke, Andre
Lu, Kun
Zhou, Huiping
Bajaj, Jasmohan S
Hylemon, Phillip B
Ting, Jenny
Popov, Yury V
Hov, Johannes Roksund
Francis, Heather L
Sartor, Ryan Balfour
Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC
title Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC
title_full Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC
title_fullStr Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC
title_full_unstemmed Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC
title_short Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC
title_sort protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of psc
topic Gut Microbiota
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751228/
https://www.ncbi.nlm.nih.gov/pubmed/35705368
http://dx.doi.org/10.1136/gutjnl-2021-326500
work_keys_str_mv AT awoniyimuyiwa protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT wangjeremy protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT ngobilly protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT meadowsvik protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT tamjason protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT viswanathanamba protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT laiyunjia protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT montgomerystephanie protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT farmermorgan protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT kummenmartin protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT thingholmlouise protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT schrammchristoph protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT bangcorinna protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT frankeandre protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT lukun protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT zhouhuiping protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT bajajjasmohans protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT hylemonphillipb protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT tingjenny protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT popovyuryv protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT hovjohannesroksund protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT francisheatherl protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc
AT sartorryanbalfour protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc